Stockscreener 앱 받기
0.78
4.42%
-0.0361
시간 외 거래:
.78
전일 마감가:
$0.8161
열려 있는:
$0.81
하루 거래량:
458.93K
Relative Volume:
0.40
시가총액:
$61.04M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-39.00
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
-2.05%
1개월 성능:
-10.47%
6개월 성능:
-38.58%
1년 성능:
-46.21%
1일 변동 폭
$0.7715
$0.8243
1주일 범위
$0.7715
$0.829
52주 변동 폭
$0.75
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
0.78 | 61.04M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average – Should You Sell? - Defense World
CytomX Therapeutics Inc [CTMX] Chief Business Officer makes an insider purchase of 4,181 shares worth 5139.0. - Knox Daily
CTMX stock touches 52-week low at $0.76 amid market challenges - MSN
Taking a Closer Look At CytomX Therapeutics Inc (CTMX) Following Its Recent Trade - Knox Daily
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77 - MarketBeat
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - Defense World
CytomX Therapeutics Inc (CTMX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Financial Health Check: Examining Universe Pharmaceuticals INC (UPC)’s Key Ratios - The Dwinnex
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter
CytomX Therapeutics Inc (CTMX) Shares Down Despite Recent Market Volatility - The News Heater
CytomX Therapeutics Inc Inc. (CTMX) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Analysts review CytomX Therapeutics Inc’s rating - Knox Daily
A stock that deserves closer examination: CytomX Therapeutics Inc (CTMX) - US Post News
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - Simply Wall St
CytomX Therapeutics Announces Executive Departure and Severance - TipRanks
Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago - Yahoo Finance
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - ACCESS Newswire
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - Yahoo Finance
Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4% - MarketBeat
Jane Street Group LLC Decreases Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
Bay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staff - MSN
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - Yahoo Finance
CytomX stock plunges to 52-week low, touches $0.83 By Investing.com - Investing.com Canada
CytomX stock plunges to 52-week low, touches $0.83 - Investing.com India
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77 - MarketBeat
Bay Area biotech firm once worth $2.3 billion lays off 40% of staff - SFGATE
Geode Capital Management LLC Has $948,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down - Yahoo Finance
CytomX Therapeutics’ (CTMX) Neutral Rating Reiterated at HC Wainwright - Defense World
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - Nasdaq
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CytomX Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
CytomX falls after portfolio shakeup, job cuts - MSN
CytomX Therapeutics' SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
CytomX stock falls on portfolio shakeup (CTMX:NASDAQ) - Seeking Alpha
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy - Yahoo Finance
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities - BioSpace
CytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC Wainwright - MarketBeat
CytomX refocuses on key cancer drug, extends cash runway - Investing.com India
CTMXCytomX Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
CytomX announces restructuring, staff cuts to extend cash runway - Investing.com
CytomX announces restructuring, staff cuts to extend cash runway By Investing.com - Investing.com South Africa
CytomX refocuses on key cancer drug, extends cash runway By Investing.com - Investing.com Canada
Peninsula biotech to lay off 40% of workforce as it restructures - The Business Journals
CytomX Therapeutics to Cut 40% of Workforce - MarketWatch
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytomx Therapeutics Inc 주식 (CTMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
| McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
0.27%
3.05%
자본화:
|
볼륨(24시간):